Advice

following a full submission:

dapagliflozin (Forxiga®) is accepted for use within NHSScotland.

Indication under review: In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥27kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Dapagliflozin in combination with insulin improved glycaemic control compared with insulin alone in adult patients with inadequately controlled type 1 diabetes.

Medicine details

Medicine name:
dapagliflozin (Forxiga)
SMC ID:
SMC2185
Indication:

In adults for the treatment of insufficiently controlled T1DM as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Accepted
Date advice published:
09 September 2019